ClinicalTrials.gg

Program

Interferon Beta-1a Inhalation Solution SNG001

Its studies are mostly in COVID-19 · Pneumonia, Viral, led by Synairgen Research.

Furthest: phase 3, since Jan 28, 20213 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Synairgen Research30 open or runningphase 3since Jan 28, 2021Apr 24, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 24, 2020First study: phase 2 study in COVID-19First studyNCT04385095 · 221 enrolled · United Kingdom
  2. Jan 28, 2021Phase 3 study in COVID-19NCT04732949 · 623 enrolled · United States, Argentina, Belgium and more
  3. May 22, 2025Phase 2 study in Pneumonia, ViralNCT06999603 · 11 enrolled · United States, United Kingdom

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06999603Pneumonia, Viral · United States, United Kingdom2TerminatedMar 13, 202611
NCT04732949COVID-19 · United States, Argentina, Belgium and more3CompletedDec 15, 2021623
NCT04385095COVID-19 · United Kingdom2CompletedFeb 17, 2021221

How it is read

Names in the registry

  • “SNG001”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.